Abstract:Background Accumulating evidence shows that m6A regulates oncogene and tumor suppressor gene expression, thus playing a dual role in cancer. Likewise, there is a close relationship between the immune system and tumor development and progression. However, for glioblastoma, m6A-associated immunological markers remain to be identified. Methods We obtained gene expression, mutation, and clinical data on glioblastoma from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. Next, we performed univariate COX–least absolute shrinkage and selection operator (LASSO)–multivariate COX regression analyses to establish a prognostic gene signature and develop a corresponding dynamic nomogram application. We then carried out a clustering analysis twice to categorize all samples according to their m6A-regulating and m6A-associated immune gene expression levels (high, medium, and low) and calculated their m6A score. Finally, we performed quantitative reverse transcription-polymerase chain reaction, cell counting kit-8, cell stemness detection, cell migration, and apoptosis detection in vitro assays to determine the biological role of CD81 in glioblastoma cells. Results Our glioblastoma risk score model had extremely high prediction efficacy, with the area under the receiver operating characteristic curve reaching 0.9. The web version of the dynamic nomogram application allows rapid and accurate calculation of patients’ survival odds. Survival curves and Sankey diagrams indicated that the high-m6A score group corresponded to the groups expressing medium and low m6A-regulating gene levels and high m6A-associated prognostic immune gene levels. Moreover, these groups displayed lower survival rates and higher immune infiltration. Based on the gene set enrichment analysis, the pathophysiological mechanism may be related to the activation of the immunosuppressive function and related signaling pathways. Moreover, the risk score model allowed us to perform immunotherapy benefit assessment. Finally, silencing CD81 in vitro significantly suppressed proliferation, stemness, and migration and facilitated apoptosis in glioblastoma cells. Conclusion We developed an accurate and efficient prognostic model. Furthermore, the correlation analysis of different stratification methods with tumor microenvironment provided a basis for further pathophysiological mechanism exploration. Finally, CD81 may serve as a diagnostic and prognostic biomarker in glioblastoma.

A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma

Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden

Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration

Prognostic Nomograms for Patients with Metastatic Gastric Cancer: A Large Population-Based Cohort Study and External Validation

A Machine Learning‐based Survival Prediction Model of High Grade Glioma by Integration of Clinical and Dose‐volume Histogram Parameters

Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study

Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study

Development and validation of a machine learning algorithm for predicting diffuse midline glioma, H3 K27-altered, H3 K27 wild-type high-grade glioma, and primary CNS lymphoma of the brain midline in adults

A Survival Nomogram Model Constructed with Common Clinical Characteristics to Assist Clinical Decisions for Diffuse Low-Grade Gliomas: A Population Analysis Based on SEER Database

A prognostic model based on CGGA and TCGA databases for predicting outcome of glioma patients.

Nomogram Predicts Prognostic Factors for Head and Neck Cutaneous Melanoma: A Population-Based Analysis

Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics

Development and validation of a nomogram to predict overall survival in patients with glioma: a population-based study

Deep learning-based prediction of H3K27M alteration in diffuse midline gliomas based on whole-brain MRI

A Study on Prognosis of Diffuse Glioma Based on Clinical Factors and Magnetic Resonance Imaging Radiomics

Clinically Available and Reproducible Prediction Models for IDH and CDKN2A/B Gene Status in Adult-type Diffuse Gliomas

Prognostic evaluation of patients with glioblastoma using a new score prediction model.

Differences in Survival Prognosticators Between Children and Adults with H3K27M‐mutant Diffuse Midline Glioma

A nomogram to predict cancer-specific mortality in adult patients with malignant meningioma: a competing risk analysis

Development of a Novel Prognostic Model of Glioblastoma Based on M6a-Associated Immune Genes and Identification of a New Biomarker

Development and Validation of a Nomogram Model Based on Hematological Indicators for Predicting the Prognosis of Diffused Gliomas